PLATELET-RICH PLASMA THERAPY CLINIC BUSINESS PLAN
I. Executive Summary
Company Description
The clinic's trade name is not disclosed. It is a physician-led regenerative medicine practice based in Austin, Texas, launching in 2026 that specializes exclusively in Platelet-Rich Plasma (PRP) therapies for orthopedic, hair restoration, and aesthetic indications. We use FDA-cleared technology to deliver natural, minimally invasive treatments on a high-margin, cash-pay basis. One sentence: physician-led PRP clinic in Austin focused on safe, high-margin regenerative care.
Core activities include physician consultations, in-clinic PRP preparation and administration, post-procedure follow-up, and referral partnerships with orthopedic and dermatology practices. What sets us apart is exclusive focus on PRP, physician oversight at every step, and use of FDA-cleared devices to drive clinical confidence and premium pricing. Target patients are adults seeking non-surgical orthopedic relief, hair restoration, or aesthetic improvement in the Austin market. Short-term goals are to open in 2026 and establish a referral and repeat-patient base; long-term goals are to scale regionally while keeping physician-led clinical governance. One sentence: launch in 2026, build a referral base, then scale regionally under physician governance.
Problem
Millions of Americans with chronic joint pain, osteoarthritis, hair thinning, and visible aging lack effective, non-surgical, physician-led regenerative options that deliver durable, measurable results; current synthetics, drugs, and surgical routes often cause side effects, temporary outcomes, long recoveries, or unmet patient expectations.
Our Austin, Texas clinic launching in 2026 fills this gap with a physician-led Platelet-Rich Plasma (PRP) specialty practice offering FDA-cleared technology, cash-pay pricing, and high-margin services—providing a safer, natural alternative and targeting $1,887,000 in Year 1 revenue. One-liner: patients need safe, regenerative, physician-led alternatives tied to measurable outcomes.
Solution
Millions of Americans seek natural, minimally invasive alternatives to surgery for chronic joint pain and hair loss; synthetic options often give temporary relief and carry side effects. We deliver physician-led, centrifuge-concentrated Platelet-Rich Plasma (PRP) therapy as a targeted alternative across orthopedic, aesthetic, and hair restoration needs, with measurable outcomes and little-to-no downtime.
Core services include guided PRP injections for joint pain, scalp PRP for pattern hair thinning, and aesthetic PRP for skin improvement. Clinical leadership scales from 1.0 Medical Director in 2026 to 2.0 by 2029, supporting a Year 5 revenue target of $11,132,000. One line: Physician-led, centrifuge-concentrated PRP that restores function and confidence.
Mission Statement
Our mission is to restore function, confidence, and vitality through regenerative medicine by delivering safe, natural, physician-led PRP therapies that empower the body to heal itself. We commit to clinical excellence, patient-centered care, and continuous advancement of regenerative protocols. We strive to be the leading specialist in non-surgical joint and aesthetic restoration in the United States.
Key Success Factors
Our clinic's success rests on focused clinical specialization, trusted leadership, steady demand generation, fast unit economics, and proven equipment.
-
100% specialization in PRP delivers clinical expertise and clear market positioning.
-
Physician-led model builds patient trust and drives superior clinical outcomes.
-
Robust digital marketing sustains high practitioner capacity and consistent lead flow.
-
Efficient operations enable a 1-month breakeven and a 6-month payback period.
-
FDA-cleared equipment ensures consistent, reliable clinical results.
Financial Summary
Brief financial snapshot for the Executive Summary.
Ratio |
2026 |
2027 |
2028 |
Projected Revenue |
$1,887,000 |
$3,046,000 |
$5,300,000 |
Projected EBITDA |
$837,000 |
$1,677,000 |
$3,378,000 |
Expected ROI |
24.89% |
24.89% |
24.89% |
Financial requirements: minimum cash $748,000 (required Feb-26); breakeven Jan-26; payback 6 months. Project returns: IRR 24.89% and ROE 20.58%.
Strong cash-on-cash returns and rapid breakeven support a high-growth, high-margin clinic model.
Funding Requirements
Minimum cash required is $748,000; target IRR 24.89%, breakeven January 2026, payback 6 months.
Categories |
Amount, USD |
Initial CAPEX (clinic buildout, equipment) |
$286,500 |
Working capital |
$461,500 |
Total funding required |
$748,000 |
One-liner: Minimum cash required is $748,000; projected Year 1 revenue $1,887,000, Year 5 $11,132,000.